Scholarlink

<p>Cystic echinococcosis (CE) is a neglected zoonotic disease that causes significant economic losses in livestock and poses health risks to humans, necessitating improved diagnostic and therapeutic strategies. This study investigates CE in donkeys using a multifaceted approach that includes molecular identification, gene expression analysis, serum biochemical profiling, histopathological and immunohistochemical examination, and in vitro drug efficacy evaluation. Molecular analysis of hydatid cyst protoscolices (HC-PSCs) from infected donkey livers and lungs revealed a high similarity to <i>Echinococcus equinus</i> (GenBank accession: PP407081). Additionally, gene expression analysis indicated significant increases (<i>P</i> &lt; 0.0001) in interleukin 1β (<i>IL-1β</i>) and interferon γ (<i>IFN-γ</i>) levels in lung and liver homogenates. Serum biochemical analysis showed elevated aspartate transaminase (<i>AST</i>), alkaline phosphatase (<i>ALP</i>), and globulin levels, alongside decreased albumin compared to non-infected controls. Histopathological examination revealed notable alterations in pulmonary and hepatic tissues associated with hydatid cyst infection. Immunohistochemical analysis showed increased expression of nuclear factor kappa B (<i>NF-κB</i>), tumor necrosis factor-α (<i>TNF-α</i>), and toll-like receptor-4 (<i>TLR-4</i>), indicating a robust inflammatory response. In vitro drug evaluations revealed that Paroxetine (at concentrations of 2.5, and 5&#xa0;mg/mL) demonstrated the highest efficacy among repurposed drugs against HC-PSCs, resulting in the greatest cell mortality. Colmediten followed closely in effectiveness, whereas both Brufen and Ator exhibited minimal effects. This study identifies Paroxetine as a promising alternative treatment for hydatidosis and provides a framework for investigating other parasitic infections and novel therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multifaceted analysis of equine cystic echinococcosis: genotyping, immunopathology, and screening of repurposed drugs against E. equinus protoscolices

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月17日

查看全文
  • Noha Madbouly Taha,
  • Mai A. Salem,
  • Mohamed A. El-Saied,
  • Faten F. Mohammed,
  • Mohamed Kamel,
  • Mohamed M. El-Bahy,
  • Reem M. Ramadan

摘要

Cystic echinococcosis (CE) is a neglected zoonotic disease that causes significant economic losses in livestock and poses health risks to humans, necessitating improved diagnostic and therapeutic strategies. This study investigates CE in donkeys using a multifaceted approach that includes molecular identification, gene expression analysis, serum biochemical profiling, histopathological and immunohistochemical examination, and in vitro drug efficacy evaluation. Molecular analysis of hydatid cyst protoscolices (HC-PSCs) from infected donkey livers and lungs revealed a high similarity to Echinococcus equinus (GenBank accession: PP407081). Additionally, gene expression analysis indicated significant increases (P < 0.0001) in interleukin 1β (IL-1β) and interferon γ (IFN-γ) levels in lung and liver homogenates. Serum biochemical analysis showed elevated aspartate transaminase (AST), alkaline phosphatase (ALP), and globulin levels, alongside decreased albumin compared to non-infected controls. Histopathological examination revealed notable alterations in pulmonary and hepatic tissues associated with hydatid cyst infection. Immunohistochemical analysis showed increased expression of nuclear factor kappa B (NF-κB), tumor necrosis factor-α (TNF-α), and toll-like receptor-4 (TLR-4), indicating a robust inflammatory response. In vitro drug evaluations revealed that Paroxetine (at concentrations of 2.5, and 5 mg/mL) demonstrated the highest efficacy among repurposed drugs against HC-PSCs, resulting in the greatest cell mortality. Colmediten followed closely in effectiveness, whereas both Brufen and Ator exhibited minimal effects. This study identifies Paroxetine as a promising alternative treatment for hydatidosis and provides a framework for investigating other parasitic infections and novel therapies.